Paper39585482
Therapeutic effect of total glucosides of paeony on IgA vasculitis nephritis: progress and prospects.
Wang Z and 9 others. Mol Biol Rep, 2024. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Therapeutic effect of total glucosides of paeony on IgA vasculitis nephritis: progress and prospects. Papers, record 39585482. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39585482
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Therapeutic effect of total glucosides of paeony on IgA vasculitis nephritis: progress and prospects.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glucosides | Major topic |
| Paeonia | Major topic |
| Humans | |
| Animals | |
| IgA Vasculitis | |
| Immunoglobulin A | |
| Glomerulonephritis, IGA | |
| Vasculitis | |
| Nephritis |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82160922 | National Natural Science Foundation of China | PubMed |
Source PubMed
References55
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30879080 | European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. | Rheumatology (Oxford) | 2019 | https://conductscience.org/library/papers/30879080 | PubMed |
| 2 | 36739540 | Demographic and clinical features of pediatric vasculitis: a single-center study. | ARP Rheumatol | 2023 | https://conductscience.org/library/papers/36739540 | PubMed |
| 3 | 32384035 | Henoch-Schönlein Purpura in Children: An Updated Review. | Curr Pediatr Rev | 2020 | https://conductscience.org/library/papers/32384035 | PubMed |
| 4 | 36915829 | Diagnostic and Management Strategies of IgA Vasculitis Nephritis/Henoch-Schönlein Purpura Nephritis in Pediatric Patients: Current Perspectives. | Pediatric Health Med Ther | 2023 | https://conductscience.org/library/papers/36915829 | PubMed |
| 5 | 24134307 | Henoch-Schönlein purpura in children. | J Paediatr Child Health | 2013 | https://conductscience.org/library/papers/24134307 | PubMed |
| 6 | 37904705 | Combined use of total glucosides of paeony and hydroxychloroquine in primary Sjögren's syndrome: A systematic review. | Immun Inflamm Dis | 2023 | https://conductscience.org/library/papers/37904705 | PubMed |
| 7 | 37402434 | Efficacy and safety of total glucosides of paeony in the treatment of 5 types of inflammatory arthritis: A systematic review and meta-analysis. | Pharmacol Res | 2023 | https://conductscience.org/library/papers/37402434 | PubMed |
| 8 | 31836457 | Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony. | Pharmacol Ther | 2020 | https://conductscience.org/library/papers/31836457 | PubMed |
| 9 | 24325071 | [Progress of pharmacological actions of total glucosides of paeony in treating diabetic nephropathy]. | Zhongguo Zhong Xi Yi Jie He Za Zhi | 2013 | https://conductscience.org/library/papers/24325071 | PubMed |
| 10 | 30949054 | Gut Microbiota-Based Pharmacokinetics and the Antidepressant Mechanism of Paeoniflorin. | Front Pharmacol | 2019 | https://conductscience.org/library/papers/30949054 | PubMed |
| 11 | 33305640 | Glycyrrhizic acid-based self-assembled micelles for improving oral bioavailability of paeoniflorin. | Drug Dev Ind Pharm | 2021 | https://conductscience.org/library/papers/33305640 | PubMed |
| 12 | 32989282 | WNT-β-catenin signalling - a versatile player in kidney injury and repair. | Nat Rev Nephrol | 2021 | https://conductscience.org/library/papers/32989282 | PubMed |
| 13 | 23247788 | [Predictive factors of severe Henoch-Schonlein nephritis in children: report of 34 cases]. | Tunis Med | 2012 | https://conductscience.org/library/papers/23247788 | PubMed |
| 14 | 34483931 | Targeting the Wnt/β-Catenin Signaling Pathway as a Potential Therapeutic Strategy in Renal Tubulointerstitial Fibrosis. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34483931 | PubMed |
| 15 | 24269653 | β-Catenin-dependent pathway activation by both promiscuous "canonical" WNT3a-, and specific "noncanonical" WNT4- and WNT5a-FZD receptor combinations with strong differences in LRP5 and LRP6 dependency. | Cell Signal | 2014 | https://conductscience.org/library/papers/24269653 | PubMed |
| 16 | 21350016 | Canonical Wnt9b signaling balances progenitor cell expansion and differentiation during kidney development. | Development | 2011 | https://conductscience.org/library/papers/21350016 | PubMed |
| 17 | 25803581 | Stromally expressed β-catenin modulates Wnt9b signaling in the ureteric epithelium. | PLoS One | 2015 | https://conductscience.org/library/papers/25803581 | PubMed |
| 18 | 25612449 | [Effect of total glucosides of paeony on Wnt/β-catenin signal transduction pathway expression in kidney of diabetic rats]. | Zhongguo Zhong Yao Za Zhi | 2014 | https://conductscience.org/library/papers/25612449 | PubMed |
| 19 | 32393431 | Total glucosides of paeony (Paeonia lactiflora) alleviates blood-brain barrier disruption and cerebral ischemia/reperfusion injury in rats via suppressing inflammation and apoptosis. | Pharmazie | 2020 | https://conductscience.org/library/papers/32393431 | PubMed |
| 20 | 29694958 | Current Mechanistic Concepts in Ischemia and Reperfusion Injury. | Cell Physiol Biochem | 2018 | https://conductscience.org/library/papers/29694958 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42634806 | Network Pharmacology-Metabolomics Integration Reveals the Multiple Targets and Mechanisms of Total Glucosides of Paeony Against Ulcerative Colitis. | J Inflamm Res | 2026 | https://conductscience.org/library/papers/42634806 | PubMed |
| 40354007 | Feasibility analysis and development trend of nanomaterials for the treatment of pancreatic cancer. | Discov Nano | 2025 | https://conductscience.org/library/papers/40354007 | PubMed |
| 40241343 | Paeoniflorin Protects Retinal Pigment Epithelial Cells from High Glucose-Induced Oxidative Damage by Activating Nrf2-Mediated HO-1 Signaling. | Biomol Ther (Seoul) | 2025 | https://conductscience.org/library/papers/40241343 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD79A | 973 | PubTator's text mining | https://conductscience.org/library/genes/973 | NCBI Gene |
| CTNNB1 | 1499 | PubTator's text mining | https://conductscience.org/library/genes/1499 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39585482
GET https://conductscience.org/api/papers/v1/39585482/references?page=2